About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Nashville | 288 Studies

Clinical Trials MelanomaNashville

Melanoma Clinical Trials in Nashville

Find 288 clinical trials for melanoma near Nashville, Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 181-200 of 288 trials

TerminatedA Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsThe goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells.NCT02452424·Scottsdale, Arizona and 11 others Active not recruitingIpilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryThis randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that…NCT01274338·Birmingham, Alabama and 936 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.NCT06346067·Phoenix, Arizona and 58 others

RecruitingA Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsThis is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent…NCT06326411·San Francisco, California and 22 others

TerminatedStudy of IK-595 in RAS- or RAF-altered Advanced TumorsThis is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary…NCT06270082·Duarte, California and 14 others

CompletedCP-675,206 In Patients With Advanced MelanomaThe purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanomaNCT00086489·Los Angeles, California and 8 others

CompletedStudy to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaSubjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization.NCT00055562·Tucson, Arizona and 30 others

TerminatedPF-06952229 Treatment in Adult Patients With Advanced Solid TumorsA Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.NCT03685591·Scottsdale, Arizona and 14 others

RecruitingA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or…NCT04913285·Los Angeles, California and 47 others

TerminatedA Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsThis study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part…NCT06285097·Sarasota, Florida and 9 others

CompletedDose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsThis is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.NCT00827177·Boston, Massachusetts and 3 others

UnknownVaccine Therapy for Patients With Stage III MelanomaThis is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed.NCT00052130·Tucson, Arizona and 79 others

CompletedDabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical…NCT01682083·Birmingham, Alabama and 167 others

TerminatedPAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).NCT02702492·Los Angeles, California and 7 others

Active not recruitingA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients…NCT02339571·Birmingham, Alabama and 762 others

RecruitingStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASEvaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.NCT05379985·Orange, California and 20 others

TerminatedStudy of ADCT-301 in Patients With Selected Advanced Solid TumorsThis study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors.NCT03621982·Palo Alto, California and 8 others

TerminatedTiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer.NCT04596033·Gilbert, Arizona and 7 others

RecruitingA Phase 1 of CTX-8371 in Patients With Advanced MalignanciesThis is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies.NCT06150664·Birmingham, Alabama and 11 others

TerminatedLGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaThe primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.NCT01820364·Nashville, Tennessee and 5 others

PreviousPage 10 of 15Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma